Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide Dosing Schedule PK Study
NCT04513704Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2020
- Primary completion
- Apr 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosing. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04513704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513704.